Long-term Outcomes of Endoscopic Papillary Large-balloon Dilation for Common Bile Duct Stones.
Adult
Aged
Aged, 80 and over
Catheterization
/ methods
Cholangiopancreatography, Endoscopic Retrograde
/ adverse effects
Choledocholithiasis
/ surgery
Cohort Studies
Common Bile Duct
/ surgery
Dilatation
/ methods
Female
Follow-Up Studies
Humans
Male
Middle Aged
Multivariate Analysis
Retrospective Studies
Risk Factors
Sphincterotomy, Endoscopic
/ methods
Treatment Outcome
difficult stone
endoscopic papillary balloon dilation
endoscopic retrograde cholangiopancreatography
recurrence
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
01 Apr 2020
01 Apr 2020
Historique:
pubmed:
4
12
2019
medline:
22
9
2020
entrez:
3
12
2019
Statut:
ppublish
Résumé
Objective Endoscopic papillary large-balloon dilation (EPLBD) for common bile duct (CBD) stone removal has been confirmed to be safe and effective in the short term. The long-term outcomes of EPLBD, which have not been sufficiently evaluated, were therefore investigated in this study. Methods For patients who had undergone endoscopic CBD stone removal with EPLBD between October 2011 and December 2015, follow-up surveys were conducted using a postal survey, telephone interview, or medical record review in August 2017. The main outcome measurement was the recurrence rate of CBD stones after complete stone removal with EPLBD in patients who received follow-up for more than one year. Risk factors for such recurrence were secondarily analyzed. Results Of the 98 patients treated using EPLBD, 93 (95%) were followed up after complete stone removal and analyzed for the long-term outcomes. During the mean follow-up period of 33.7±16.6 months, CBD stones recurred in 16 patients (17%) with a mean interval of 12.7±12.7 months. Univariate analyses showed that a large stone size, multiple stones, a large distal CBD diameter, and a history of cholecystectomy were significant risk factors for stone recurrence (p=0.022, 0.013, 0.001 and 0.035, respectively). The large distal CBD diameter was the only significant risk factor for stone recurrence in a multivariate analysis (hazard ratio, 1.227; p=0.031). Conclusion The long-term outcomes of EPLBD for CBD stones, including the rate of stone recurrence, were found to be acceptable. A large distal CBD diameter was an independent risk factor for stone recurrence.
Identifiants
pubmed: 31787702
doi: 10.2169/internalmedicine.3881-19
pmc: PMC7184081
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
891-899Références
Dig Endosc. 2018 Jul;30(4):493-500
pubmed: 29399885
Dig Endosc. 2018 May;30(3):293-309
pubmed: 29411902
J Gastroenterol Hepatol. 2015 Jan;30(1):223-9
pubmed: 24995677
Gastrointest Endosc. 2010 Mar;71(3):446-54
pubmed: 20189503
Dig Endosc. 2019 Jan;31(1):59-68
pubmed: 29943385
Gastrointest Endosc. 2017 Apr;85(4):782-790.e1
pubmed: 27597425
Biomed Res Int. 2015;2015:673103
pubmed: 25756050
Surg Endosc. 2017 Feb;31(2):650-655
pubmed: 27317037
World J Gastroenterol. 2014 May 14;20(18):5548-56
pubmed: 24833886
Clin Endosc. 2013 Nov;46(6):637-42
pubmed: 24340257
J Gastroenterol. 2012 Jun;47(6):655-63
pubmed: 22361862
Gastroenterol Res Pract. 2018 Jul 2;2018:6430701
pubmed: 30057600
Gut Liver. 2012 Jan;6(1):107-12
pubmed: 22375179
World J Gastroenterol. 2013 Dec 14;19(46):8580-94
pubmed: 24379575
Dig Dis Sci. 2016 Oct;61(10):3045-3053
pubmed: 27286878
Scand J Gastroenterol. 2014 Jan;49(1):121-8
pubmed: 24164293
Gastrointest Endosc. 2003 Feb;57(2):156-9
pubmed: 12556775
Lancet. 2002 Sep 7;360(9335):761-5
pubmed: 12241833